The DOI matches its Crossref record.
A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
Abstract
BACKGROUND: Vesnarinone, an inotropic drug, was shown in a short-term placebo-controlled trial to improve survival markedly in patients with severe heart failure when given at a dose of 60 mg per day, but there was a trend toward an adverse effect on survival when the dose was 120 mg per day. In a longer-term study, we evaluated the effects of daily doses of 60 mg or 30 mg of vesnarinone, as compared with placebo, on mortality and morbidity. METHODS: We enrolled 3833 patients who had symptoms of New York Heart Association class III or IV heart failure and a left ventricular ejection fraction of 30 percent or less despite optimal treatment. The mean follow-up was 286 days. RESULTS: There were significantly fewer deaths in the placebo group (242 deaths, or 18.9 percent) than in the 60-mg vesnarinone group (292 deaths, or 22.9 percent) and longer survival (P=0.02). The increase in mortality with vesnarinone was attributed to an increase in sudden death, presumed to be due to arrhythmia. The quality of life had improved significantly more in the 60-mg vesnarinone group than in the placebo group at 8 weeks (P<0.001) and 16 weeks (P=0.003) after randomization. Trends in mortality and in measures of the quality of life in the 30-mg vesnarinone group were similar to those in the 60-mg group but not significantly different from those in the placebo group. Agranulocytosis occurred in 1.2 percent of the patients given 60 mg of vesnarinone per day and 0.2 percent of those given 30 mg of vesnarinone. CONCLUSIONS: Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia. A short-term benefit in terms of the quality of life raises issues about the appropriate therapeutic goal in treating heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Cardiac Resynchronization in Chronic Heart Failure
Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013168 · Cited by 4,648
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Cohn, J. N., Ferrari, R., & Sharpe, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00630-0 · Cited by 2,161
Self-citationChung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Preferences for quality of life or survival expressed by patients with heart failure
Lewis, E. F., Johnson, P. A., Johnson, W., Collins, C., Griffin, L., & Stevenson, L. W. (2001) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(01)00298-4 · Cited by 433
Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00008 · Cited by 389
Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61219-1 · Cited by 262
The agonising negative trend in monitoring of clinical trials
DeMets, D. L., Pocock, S. J., & Julian, D. G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03464-9 · Cited by 126
Self-citationTaylor, A. L., Ziesche, S., Yancy, C. W., Carson, P., Ferdinand, K., Taylor, M., Adams, K., Olukotun, A. Y., Ofili, E., Tam, S. W., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.644013 · Cited by 114
Self-citationPrinciples From Clinical Trials Relevant to Clinical Practice: Part I
Califf, R. M., & DeMets, D. L. (2002) · Circulation · doi:10.1161/01.cir.0000023260.78078.bb · Cited by 108
Self-citationDigitalis for treatment of heart failure in patients in sinus rhythm
Hood Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R., & McMurray, J. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002901.pub3 · Cited by 56
The role of inflammation in the pathogenesis of heart failure
Lisman, K. A., Stetson, S. J., Koerner, M. M., Farmer, J. A., & Torre-Amione, G. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0051-3 · Cited by 18
Medical Treatment of Peripheral Artery Disease
Gornik, H. L., & Creager, M. A. (2013) · Vascular Medicine: A Companion to Braunwald's Heart Disease · doi:10.1016/b978-1-4377-2930-6.00019-7 · Cited by 12
Metadata
- Authors
- Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., DeMets, D. L., & White, B. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-12-17
- Volume
- 339
- Issue
- 25
- Pages
- 1810-1816
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2314949940
- Cited by
- 613
- References
- 0
- FWCI
- 28.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
